Clinical trial
Study of SU011248 in Patients With Advanced Kidney Cancer
NCT00254540 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00254540 |
|---|---|
| Title | Study of SU011248 in Patients With Advanced Kidney Cancer |
| Official title | Phase II Study Of Single-Agent SU011248 In The Treatment Of Patients With Renal Cell Carcinoma |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | SU011248 capsule |
| Enrollment | 51 |
| Start date | Dec 1, 2005 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Nov 16, 2005 |
| Last update posted | Feb 23, 2010 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: